PATENT CLAIM ANALYSIS

Application Number: 15867000
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "04400A"]

Abstract:
The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.

Claim (Index 25):
The method of  claim 13 , wherein the IGF-IR AS ODN has the sequence of SEQ ID NO: 1.

Metadata:
- Claim Count in Document: 116.0
- Percentile: 86.0
- Lexical Diversity: 1.88235
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15095877', '14775667', '14257480', '12559415', '12582013']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7190730116341071
- 35 USC 102 Novelty (BERT): 0.5805336533051834
- Combined Prediction Score: 0.7052190758012147
- Mean Citation Score: 269.107612
- Max Citation Score: 524.4415
- Similarity Product: 345.1595880610347

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test